Product Description
High-affinity 3pE-Aβ binders enable lower predicted efficacious dosage levels compared to competitors, and target the plaque form of Aβ rather than earlier stages of aggregationAn optimized Fc domain increases half-life, reduces effector function and leads to clearance of bound antibodies through a mechanism that reduces pro-inflammatory cytokine release and immune exhaustion (see "Novel antibody clearance mechanism" below).The anti-TfR Delivery Module transports 3pE-Aβ antibodies into the brain at a higher concentration than naked antibodies, leading to more efficient target clearance. The proprietary scFv design also confers increased stability, reduced aggregation and lower manufacturing cost. Aliada’s ALIA-1758 has the potential to be a best-in-class therapy for the treatment of patients with Alzheimer’s disease (AD). MODEL platform-enabled by Aliada to harness transport via TfR, ALIA-1758’s strong target binder properties and improved CNS delivery offers the potential to achieve robust reduction of brain amyloid burden at lower dosage levels than other antibodies in this class. Consequently, a convenient monthly subcutaneous low-dose regimen could improve access to therapy for more patients with AD. A high-value program in its own right, ALIA-1758’s advancement also provides an opportunity to establish clinical proof-of-principle for the MODEL platform. (Sourced from: https://aliadatx.com/programs/)
Mechanisms of Action: AB Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aliada Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for ALIA-1758](https://pryzm-maps.s3.us-west-2.amazonaws.com/9current_maps.png)
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ALIA-1758-101 | P1 |
Recruiting |
Alzheimer Disease |
2025-01-01 |